Vascular endothelial growth factor is an effective biomarker for vascular dementia, not for Alzheimer's disease: A meta‐analysis

Abstract

Abstract INTRODUCTION Vascular pathology is known to contribute to dementia and vascular endothelial growth factor (VEGF) is a well‐established biomarker associated with vascular alterations. Nonetheless, research findings on VEGF in Alzheimer's disease (AD) and vascular dementia (VaD) are inconsistent across various studies. METHODS We conducted a meta‐analysis to elucidate relationships between VEGF and AD/VaD. RESULTS Twenty‐four studies were included. Pooled data showed that both blood and cerebrospinal fluid (CSF) VEGF levels were higher in VaD patients, whereas no significant difference was found between AD patients and healthy controls. However, the correlation between blood VEGF and AD was found among studies with AD pathology verification. And blood VEGF levels were higher in AD patients than controls in “age difference < 5 years” subgroup and CSF samples for European cohorts. DISCUSSION This study highlights that VEGF is more effective for the diagnosis of VaD and vascular factors are also an important contributor in AD. Highlights Vascular endothelial growth factor (VEGF) levels were higher in the vascular dementia group, but not in the overall Alzheimer's disease (AD) group. Correlation between VEGF and AD was found among studies with clear AD pathological verification. Elevated VEGF in the cerebrospinal fluid might be a diagnostic marker for AD in European populations.

Keywords

• Alzheimer's disease
• biomarker
• meta‐analysis
• vascular dementia
• vascular endothelial growth factor